Investigators sought to determine if the gemcitabine intravesical system plus intravenous cetrelimab could improve survival for patients with muscle-invasive bladder cancer who did not receive radical ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

NFL free agency is in full swing. We're tracking it all, from the best available players to signings and contract details ...

Consuming more dietary protein may benefit people with various types of muscular dystrophy, according to a recent study.

Plus, tips and testimonials from real women.

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

The most advanced new surgical procedure, AMI, addresses proprioception. This refers to the ability to sense position and movement. In an intact human arm or leg, muscles work in pairs. When a bicep ...

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

For years, the U.S. government has doubted the stories of those suffering from AHI, commonly called Havana Syndrome. Now, ...

A senior FDC official said the product is a “failed therapy” and confirmed that regulators have asked uniQure to run a new trial to prove the therapy actually helps Huntington’s patients. The ...